Related Experiment Video
Updated: Jun 16, 2026
An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
[Clinical trial on safety of inactivated split influenza virus vaccine, Anflu in 2007-2008]
Xu Wang1, Yan Liu, Yan-Wei Zhao
1Sinovac Biotech Co., Ltd, Beijing 100085, China.
Insights
The inactivated split influenza vaccine, Anflu, demonstrated a favorable safety profile in a large-scale population study. Few adverse events were reported, with most being mild and transient, indicating Anflu is a safe vaccine option.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Influenza remains a significant global health concern, necessitating effective vaccination strategies.
- Inactivated split influenza vaccines are widely used for seasonal influenza prevention.
- Assessing the safety of new vaccine formulations in diverse populations is crucial.
Purpose of the Study:
- To evaluate the safety and tolerability of the inactivated split influenza vaccine, Anflu.
- To assess Anflu's safety profile across a broad age range in a large-scale population.
Main Methods:
- A nationwide study involving 14 districts was conducted.
- Inactivated split influenza vaccine, Anflu, was administered to participants across various age groups (infants to elders).
- Adverse events following immunization (AEFI) were monitored for seven days post-vaccination.
Main Results:
- A total of 2,794 volunteers aged 6 months to 90 years participated.
- The overall incidence of adverse events was 6.6%, with the majority being mild reactions.
- No severe, infrequent, or novel adverse events were reported. Local reactions occurred at a rate of 2.1%, and systemic events at 5.0% (fever 3.8%).
Conclusions:
- The inactivated split influenza vaccine, Anflu, was found to be safe.
- Anflu demonstrated a favorable safety profile in a large, diverse population.
- The vaccine is well-tolerated with a low incidence of mild adverse events.
Objective:
To review the safety of the inactivated split influenza vaccine, Anflu in a large scale population.
Methods:
Selecting 14 districts national wide to inject the inactivated split influenza vaccines according schedules among infants, children, youths, adults and elder respectively. All volunteers were observed for AEFI after 7 days vaccinated.
Results:
A total of 2794 volunteers aged 6 months to 90 years were enrolled in trials. The overall rate of adverse events was 6.6%.most adverse was mild reaction. Severe, infrequent or new adverse events were not reported. The rate of local reactions was 2.1%. The rate of local pain was 1.7%. The rate of systematic adverse events was 5.0%, fever took up 3.8%.
Conclusion:
The inactivated split influenza vaccine, Anflu was safe.
